http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2013200124-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3a71b484d62ce48cc0782c2a8460ecb8 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 |
| filingDate | 2013-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31f1f104ec18e2ccc80e78eed94ff294 |
| publicationDate | 2014-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2013200124-B2 |
| titleOfInvention | Genetically modified human natural killer cell lines |
| abstract | The invention provides a natural killer cell, NK-92 modified to express an Fc receptor on the surface of the cell, such as CD 16 (FcyRIII-A), or other Fcy or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signalling protein, such as FcRI-y,TCR-Q, or to concurrently express interleukin-2(IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells. Figure 5 Redirected Cytotoxicity of NK-92-CD16 toward SKOV-3 Targets using 2B1 Bispecific Antibody 40 - IgM-transduced + 21 30 - IgM-transduced w/o 2B1 A CD16-transduced + 2B1 0 20 - L CD16-transduced w/o 2B1 0 -Y E:T Ratio |
| priorityDate | 2004-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 501.